SPYRE THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Basic
SPYRE THERAPEUTICS, INC. (SYRE) reported Net Income (Loss) Available to Common Stockholders, Basic of -$27.24 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-13.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2018-03-13
- SPYRE THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2016-12-31 was -$5.48M.
- SPYRE THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2016-09-30 was -$6.24M.
- SPYRE THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2016-06-30 was -$5.43M.
- SPYRE THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2016-03-31 was -$4.55M.
- SPYRE THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2017 was -$27.24M.
- SPYRE THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2016 was -$21.70M.
- SPYRE THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2015 was -$11.52M.
- SPYRE THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2014 was -$10.35M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$27.24M 10-K · filed 2018-03-13 | |||
| 2016-12-31 | -$5.48M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | -$11.72M derived: sum of 2 quarters · filed 2018-03-13 | -$17.15M derived: sum of 3 quarters · filed 2018-03-13 | -$21.70M 10-K · filed 2018-03-13 |
| 2016-09-30 | -$6.24M 10-Q · filed 2016-11-09 | -$11.67M derived: sum of 2 quarters · filed 2016-11-09 | -$16.21M 10-Q · filed 2016-11-09 | -$20.20M derived: sum of 4 quarters · filed 2018-03-13 |
| 2016-06-30 | -$5.43M 10-Q · filed 2016-08-09 | -$9.98M 10-Q · filed 2016-08-09 | -$13.96M derived: sum of 3 quarters · filed 2018-03-13 | -$17.38M derived: sum of 4 quarters · filed 2018-03-13 |
| 2016-03-31 | -$4.55M 10-Q · filed 2016-05-19 | -$8.53M derived: sum of 2 quarters · filed 2018-03-13 | -$11.95M derived: sum of 3 quarters · filed 2018-03-13 | -$13.37M derived: sum of 4 quarters · filed 2018-03-13 |
| 2015-12-31 | -$3.99M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | -$7.40M derived: sum of 2 quarters · filed 2018-03-13 | -$8.83M derived: sum of 3 quarters · filed 2018-03-13 | -$11.52M 10-K · filed 2018-03-13 |
| 2015-09-30 | -$3.41M 10-Q · filed 2016-11-09 | -$4.84M derived: sum of 2 quarters · filed 2016-11-09 | -$7.54M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | -$1.43M 10-Q · filed 2016-08-09 | -$4.12M 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | -$2.70M 10-Q · filed 2016-05-19 | |||
| 2014-12-31 | -$10.35M 10-K · filed 2017-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |